Phase II DESTINY-Lung01: Interim Analysis of Trastuzumab Deruxtecan in Patients With HER2-Mutated NSCLC

May 29-31, 2020; Online at meetings.asco.org/am
T-DXd was associated with a high response rate and durable responses with no new safety signals in previously treated patients with HER2-mutated NSCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 275 KB
Released: May 30, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

On-demand webcast on biomarker-driven care for patients with NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Downloadable slides for oncologists, pharmacists, and nurses: Immunotherapy and chemotherapy for extensive-stage SCLC from Clinical Care Options (CCO)

Released: May 11, 2022

On-demand webcast on HER2, HER3, and TROP2 antibody-drug conjugates in breast, gastrointestinal, and lung cancers, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Yelena Y. Janjigian, MD Sandip P. Patel, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

Downloadable summary slideset of key takeaways from a live symposium for nurses on management of EGFR ex20ins+ advanced NSCLC, from Clinical Care Options (CCO)

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Matthew Gubens, MD, MS Released: May 11, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings